ImmunomeIMNM
IMNM
About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Employees: 131
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
338% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 16
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
18% more funds holding
Funds holding: 120 [Q4 2024] → 141 (+21) [Q1 2025]
3.06% more ownership
Funds ownership: 85.41% [Q4 2024] → 88.47% (+3.06%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
8% less capital invested
Capital invested by funds: $566M [Q4 2024] → $518M (-$48M) [Q1 2025]
98% less call options, than puts
Call options by funds: $449K | Put options by funds: $29.1M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
150%
upside
Avg. target
$28
202%
upside
High target
$33
259%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Chad Messer | 150%upside $23 | Buy Initiated | 2 Apr 2025 |
Wedbush David Nierengarten | 259%upside $33 | Outperform Reiterated | 20 Mar 2025 |
Stephens & Co. Sudan Loganathan | 226%upside $30 | Overweight Reiterated | 20 Mar 2025 |
Guggenheim Michael Schmidt | 172%upside $25 | Buy Maintained | 20 Mar 2025 |
Financial journalist opinion
Based on 4 articles about IMNM published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
1 week ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 173,000 shares of common stock to 13 new employees under the Company's 2024 Inducemen.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
3 weeks ago
Immunome to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Negative
Zacks Investment Research
1 month ago
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.
Neutral
Business Wire
1 month ago
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We remain on track to share topline data for the RINGSIDE trial of varegacestat in the s.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
1 month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company's 2024 Induceme.
Positive
Seeking Alpha
1 month ago
Immunome: Transformed Pipeline Offers Multiple Catalysts
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts.
Charts implemented using Lightweight Charts™